Investors in the pharma/biotech sector eagerly wait for pipeline
updates as they play an important role in deciding whether or not
to invest in a particular company. Pipelines are of prime
importance as far as pharma/biotech companies are concerned. These
companies spend a significant amount in advancing their pipelines.
) announced top-line results from three phase III studies (CLEAR1,
CLEAR2 and CRYSTAL) on gout candidate lesinurad. The multi-center,
randomized, placebo-controlled and 12-month CLEAR1 and CLEAR2
studies evaluated the efficacy and safety of lesinurad (200 mg and
400 mg once daily) in combination with the xanthine oxidase (XO)
inhibitor allopurinol, in symptomatic gout patients not achieving
sufficient benefit on their current allopurinol dose.
Lesinurad in both doses in combination with allopurinol met the
primary endpoint in the CLEAR1 and CLEAR2 studies. Top-line data
from the studies revealed that a statistically significant higher
proportion of patients under lesinurad met the serum uric acid
(sUA) level goal (<6.0 mg/dL) at six months compared to patients
under allopurinol alone.
Meanwhile, the company also announced data from the CRYSTAL study
on lesinurad (200 mg and 400 mg once daily) in combination with
Takeda Pharmaceuticals' (
) XO inhibitor Uloric (febuxostat) in gout patients with tophi. In
the study, lesinurad 400 mg in combination with febuxostat met the
primary endpoint, while lesinurad 200 mg failed to do so at 6
The company plans to make regulatory submissions for the lesinurad
(200 mg) combination therapy. We remind investors that lesinurad
was added to AstraZeneca's pipeline with the acquisition of Ardea
Biosciences, Inc. We expect investor focus to remain on
AstraZeneca's pipeline going forward.
AstraZeneca presently carries a Zacks Rank #2 (Buy). Some
better-ranked stocks in the healthcare sector include Endo
) and Allergan (
). Both Allergan and Endo are Zacks Rank #1 (Strong Buy)
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
ENDO INTL PLC (ENDP): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.